Human CD52 (CAMPATH-1 antigen) ELISA Kit (DEIA-FN252)

Regulatory status: For research use only, not for use in diagnostic procedures.

Write a review

Size
96T
Sample
serum, plasma, cell culture supernatants, tissue homogenate
Species Reactivity
Human
Intended Use
For quantitative detection of Human CD52 (CAMPATH-1 antigen) in serum, plasma, tissue homogenates and other biological fluids.
Contents of Kit
1. 96-well strip plate (Dismountable), 1 plate
2. Lyophilized Standard, 2 vials
3. Sample/Standard dilution buffer, 20 mL
4. Biotin-detection antibody (Concentrated), 120 uL
5. Antibody dilution buffer, 10 mL
6. HRP-Streptavidin Conjugate(SABC), 120 uL
7. SABC dilution buffer, 10 mL
8. TMB substrate, 10 mL
9. Stop solution, 10 mL
10. Wash buffer (25X), 30 mL
11. Plate Sealer, 5 pieces
12. Product Manual, 1 copy
Storage
Store the unopened product at 2 - 8 °C. Do not use past expiration date.
Precision
Intra-Assay: CV<8%
Inter-Assay: CV<10%
Detection Range
0.312-20 ng/mL
Sensitivity
0.188 ng/mL
Standard Curve

Citations


Have you cited DEIA-FN252 in a publication? Let us know and earn a reward for your research.

Customer Reviews


Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket

References


A POLYCLONAL POPULATION OF PIGA MUTANT CD52 AND GPI-ANCHOR NEGATIVE T-CELLS CAN GIVE EARLY IMMUNE PROTECTION AFTER ALEMTUZUMAB-BASED T-CELL DEPLETED ALLOGENEIC STEM CELL TRANSPLANTATION

HAEMATOLOGICA

Authors: Loeff, F.; Falkenburg, J. F.; Hageman, L.; Veld, S.; de Meent, M. van; Halkes, S.; Jedema, I.

Lowering the alemtuzumab dose in reduced intensity conditioning allogeneic hematopoietic cell transplantation is associated with a favorable early intense natural killer cell recovery

CYTOTHERAPY

Authors: Gaertner, Frank; Hieke, Stefanie; Finke, Juergen; Bertz, Hartmut

Background aims. The anti-CD52 monoclonal antibody alemtuzumab is employed in allogeneic hematopoietic cell transplantation (alloHCT) for the prevention of graft-versus-host disease (GVHD). However, its optimal dosing in this setting has not been determined yet. We compared three different alemtuzumab dose levels in reduced intensity conditioning (RIC) alloHCT with respect to lymphocyte recovery and outcome. Methods. In 127 consecutive patients with predominantly advanced stage hematologic malignancies, a first alloHCT after RIC was performed, applying a fludarabine-based protocol (in 93% FBM: fludarabine, bis-chloroethyl-nitrosourea [BCNU] and melphalan). For GVHD prophylaxis, cyclosporine and alemtuzumab at three different dose levels (40 mg, 20 mg, 10 mg) were administered. Recovery of the peripheral blood (PB) lymphocyte sub-populations and clinical outcome were determined with regard to the alemtuzumab dose. Results. Natural killer (NK) cell concentrations in PB around day +30 correlated inversely with the alerntuzumab dose, whereas other PB lymphocyte subtypes remained essentially unaffected by dosing of alemtuzumab. Lower alemtuzumab doses were associated with a tendency toward improved overall survival mainly during the early post-transplantation months. With regard to the PB NK cell concentration around day +30, "early intense NK cell reconstituters" tended to show an overall survival benefit. Conclusions. An alemtuzumab dose reduction to only 10-20 mg provides sufficient GVHD prophylaxis and supports improved NK cell regeneration early after alloHCT in PB ("NK cell saving effect"), which may have a positive effect on overall survival.

Online Inquiry

Name:
Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:

Related Products

Related Resources

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

Inquiry Basket